It’s been a year and a half since I posted the “screen play” about our hero and her little company’s epic quest to improve the survival, with vastly better QOL, of GBM patients and ultimately for all solid tumor instances.
Although I thought the P3 trial results would have been known by now, the plot has continued and thickened. The recent positive plot elements include the sharing of encouraging blinded data, the hiring of IR and CFO, and most importantly that people (trial participants) apparently are living several years and more beyond their enrollment in the trial.
Among the negatives are that the Sawston funds appear to have been consumed, additional dilutions/fund raises, continued sparse communication from the company, and that data lock, TLD release, and success/failure of the trial are still not achieved. The share price remaining in the 21-25 cent range for a late P3 trial biotech with encouraging results shakes the logic around success while some other biotechs that are not this far along have their share price and market cap grow.
Is this a compelling suspenseful plot or what?
Even staunch Longs such as myself are repeatedly tested by weighing the positives and negatives and running through the logic trail over and over.
I guess I’m an optimist, continuing to come out net positive that the plot will prove to be an inspiring set of outcomes and a major advance medically, for patients, investors, and our hero’s,
